A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Clinical trial NCT05485753 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05485753
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma

Start date: 2023-02-10
Primary completion: 2025-12-01
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.